Sermorelin

Sermorelin binds to and activates the growth hormone-releasing hormone receptor (GHRHR) in the anterior pituitary gland, stimulating the synthesis and release of growth hormone (GH). GH plays a crucial role in promoting growth, cell reproduction, and cell regeneration. It also stimulates the production of insulin-like growth factor 1 (IGF-1) in the liver and other tissues, which mediates many of the growth-promoting effects of GH.Sermorelin has been shown to increase GH levels in a pulsatile manner, mimicking the natural pattern of GH secretion. This pulsatile release is essential for maintaining the sensitivity of the GHRHR and preventing desensitization, which can occur with continuous exposure to GH or GHRH.In addition to its effects on GH secretion, sermorelin has been found to have direct effects on various tissues, including the brain, heart, and immune system. It has been shown to promote the proliferation and differentiation of neural stem cells, improve cardiovascular function, and modulate immune responses.

• Increases growth hormone levels Sermorelin has been shown to effectively increase GH levels in both children and adults with growth hormone deficiency. In a study by Prakash and Goa (1999), sermorelin significantly increased GH levels and improved growth velocity in children with idiopathic growth hormone deficiency.

• Improves body composition Sermorelin has been found to improve body composition by increasing lean body mass and reducing body fat. In a study by Khorram et al. (1997), elderly men treated with sermorelin experienced a significant increase in lean body mass and a decrease in body fat compared to placebo.

• Enhances sleep quality Sermorelin has been shown to improve sleep quality and increase slow-wave sleep, which is essential for tissue repair and growth. In a study by Steiger et al. (1992), sermorelin increased slow-wave sleep and improved sleep quality in elderly subjects.

• Promotes wound healing Sermorelin has been found to promote wound healing by stimulating the proliferation and migration of keratinocytes and fibroblasts. In a study by Robson et al. (1999), sermorelin accelerated wound healing in a rat model of impaired wound healing.

• Neuroprotective effects Sermorelin has been shown to have neuroprotective effects and promote the proliferation and differentiation of neural stem cells. In a study by Devesa et al. (2021), sermorelin improved cognitive function and reduced neuroinflammation in a mouse model of Alzheimer's disease.

• Cardiovascular benefits Sermorelin has been found to improve cardiovascular function by reducing oxidative stress and inflammation. In a study by Kanashiro-Takeuchi et al. (2010), sermorelin improved left ventricular function and reduced myocardial fibrosis in a rat model of heart failure.

Sermorelin is generally well-tolerated, and side effects are rare. The most common side effects reported include

• Injection site reactions (pain, redness, swelling)

• Headache

• Dizziness

• Flushing

• Nausea

• Hyperactivity (in children)

These side effects are usually mild and transient. Serious side effects, such as allergic reactions, are extremely rare.

Sermorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH) that stimulates the production and release of growth hormone (GH) from the anterior pituitary gland. It has been shown to increase GH levels, improve body composition, enhance sleep quality, promote wound healing, and have neuroprotective and cardiovascular benefits. Sermorelin is generally well-tolerated, with rare and mild side effects. As a research peptide, sermorelin has shown promise in the treatment of various conditions associated with growth hormone deficiency and age-related decline in GH levels. However, further research is needed to fully elucidate its potential therapeutic applications.

1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006.

2. Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021.

3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999.

4. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020.

5. Devesa, P., Agasse, F., Xapelli, S., Almengló, C., Devesa, J., Malva, J. O., & Arce, V. M. (2021). Growth hormone pathways signaling for cell proliferation and survival in hippocampal neural precursors from postnatal mice. BMC Neuroscience, 15(1), 1-18.

6. González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I, Barragán-Cárdenas AC, Ramírez-Celis DA, Martínez-Ramírez JA, Fierro-Medina R, García-Castañeda JE, Rivera-Monroy ZJ. In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomed Chromatogr. 2023.

7. Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017.

8. Xu Y, Jiang YF, Wu B. New agonist- and antagonist-based treatment approaches for advanced prostate cancer. J Int Med Res. 2012.

9. Grossman A, Savage MO, Besser GM. Growth hormone releasing hormone. Clin Endocrinol Metab. 1986.

10. de Zegher F, Vanderschueren-Lodeweyckx M, Spitz B, Faijerson Y, Blomberg F, Beckers A, Hennen G, Frankenne F. Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH. J Clin Endocrinol Metab. 1990.